Biogen to pay $1.25B settlement in multiple sclerosis drug case

The giant settlement and licensing agreement could help Cambridge biotech Biogen extend the life of its multiple sclerosis drug, Tecfidera, which accounts for around a third of its total revenue.
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.